Navigation Links
External beam RT for early-stage breast cancer does not increase mortality risks
Date:9/24/2013

Atlanta, September 24, 2013Early-stage breast cancer patients who receive external beam therapy (XRT) are not at higher risk for serious long-term side effects in the chest area, including increase in deaths from cardiac disease and secondary malignancies, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting.

The study utilized patient information from the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) database. It evaluated women identified as having primary Stage T1aN0 breast cancer (tumor of 5mm or less that has not spread to the lymph nodes), who received surgery, with or without post-operative radiation therapy, between 1990 and 1997. The analysis was done to determine if XRT was associated with increased mortality due to breast cancer, secondary cancer in the chest area or cardiac conditions for these patients; only patients with breast cancer (BC) identified as the first malignancy were included. The women had a median age of 55-59 and were divided into two groups: 2,397 who received XRT after surgery, and 2,988 who did not receive XRT after surgery.

Cause of death (COD) codes were used to identify cardiac mortality, breast cancer mortality, and deaths from secondary chest cancers in order to assess overall survival (OS), breast cancer survival (BCS), second-tumor specific survival and cardiac-cause specific survival (CCS), and then compared between the XRT and non-XRT groups. The incidence of mortality was compared between the XRT and non-XRT groups utilizing the Chi-Square test; and, the relative risk (RR) and associated 95 percent confidence interval (CI) were calculated. Kaplan-Meier survival analysis and log-rank test were performed to assess OS, BCS, second-tumor specific survival and CCS.

At 10 years post-treatment, OS rates were 91.6 percent for the XRT patients and 87 percent for the non-XRT group; BCS rates were 97 percent for the XRT patients and 95.7 percent for the non-XRT group; and CCS was 96.7 percent for the XRT patients and 92.7 percent for the non-XRT group.

Analysis of the data further demonstrates that, with a median follow up of 14 years, there was no statistically significant difference in deaths from subsequent non-breast cancers in the chest area, the majority of which were lung cancers. The number of deaths from cardiac causes was not significantly higher for those patients treated with XRT for left-sided breast cancer, compared to those with right-sided breast cancer among the patient sample and time period reviewed. More women from the non-XRT group died from all causes, including cardiac causes, suggesting that those patients had worse general health conditions than the women who received radiation therapy.

"Breast conserving therapy, consisting of lumpectomy and XRT, has been an excellent approach to early breast cancer treatment, offering equivalent disease control and better cosmetic results compared to mastectomy as demonstrated by multiple randomized controlled trials in the past," said Jason Ye, MD, the study's presenting author and a second-year resident in radiation oncology at Weill Cornell Medical College in New York City. "Our study's results suggest that serious long-term side effects of radiation therapy, such as increase in deaths from cardiac disease and secondary malignancies, are rare. Radiation therapy is an integral part of early stage breast cancer treatment for those who choose to have a lumpectomy instead of a mastectomy, with its benefits likely far outweighing the potential risks in majority of the cases. The field of radiation oncology is rapidly changing, with new technology constantly being introduced that may reduce these risks further. Continued long term follow up and additional studies are needed to monitor for potential long term side effects."


'/>"/>

Contact: Michelle Kirkwood
michellek@astro.org
703-286-1600
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. AED.com Supports Automated External Defibrillator (AED) Legislation in Schools in US and UK
2. North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com
3. Automated External Defibrillator Market to Reach $930 Million by 2017 - New Report by MarketsandMarkets
4. AED.com Now Offers Automated External Defibrillator (AED) Sports Packages
5. San Jose CPR Certification Now Sells AEDs (Automated External Defibrillators) and Teaches CPR/AED Certification Training Classes in San Jose, CA
6. Joan Bowman, VP External Affair, to Speak at Mid-Continental States Association of Food and Drug Officials (MCAFDO)
7. Gammapod developed at University of Maryland School of Medicine targets early-stage breast cancer
8. NIH-developed candidate dengue vaccine shows promise in early-stage trial
9. Radiation treatment after surgery improves survival for elderly women with early-stage breast cancer
10. Many options, good outcomes, for early-stage follicular lymphoma
11. Study: Majority of older, early-stage breast cancer patients benefit from radiation after lumpectomy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... Palm Beach, FL (PRWEB) , ... June 23, 2017 , ... ... 19, in Pinecrest, Florida. This is MD Now’s 28th facility overall and marks the ... S. Dixie Highway, located one mile North of The Falls shopping mall. The new ...
(Date:6/23/2017)... ... June 23, 2017 , ... American Farmer, will feature Chr. Hansen, Inc (CHR ... air fourth quarter 2017. American Farmer airs Tuesdays at 8:30aET on RFD-TV. Check your ... Chr. Hansen in Denmark in 1874 after a groundbreaking discovery of how to industrialize ...
(Date:6/23/2017)... ... 23, 2017 , ... Jusino Insurance Services, a locally owned ... greater Chicago metropolitan area, is embarking on a charity drive in conjunction with ... Founded in 1897, Hephzibah Children’s Association is one of the oldest social services ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... the Houston area with access to asset protection and financial planning services, is ... aimed at improving the lives of children with cancer and other chronic diseases. ...
(Date:6/22/2017)... (PRWEB) , ... June 22, 2017 , ... ... advisory organization, is pleased to welcome Whipple & Company as its newest Partner ... clear purpose of balancing their clients’ risk while tailoring optimized benefit packages that ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... N.Y. , May 22, 2017  Lilac ... treatment Gene-Eden-VIR/Novirin, announces the launch of a ... English, the results of a clinical study that ... year treatment with Gene-Eden-VIR/Novirin in individuals suffering from ... to note that there are no other treatments ...
(Date:5/18/2017)...  Two Bayer U.S. Pharmaceutical leaders received top awards ... 28 th Woman of the Year ... longstanding mission of furthering the advancement and impact of ... Cindy Powell-Steffen , senior director of brand activation and ... Libby Howe , a regional business manager for New ...
(Date:5/15/2017)... 2017  Amy Baxter MD, chief executive officer and ... pain relief, was awarded a 2017 Top 40 Healthcare ... recognized at the MM&M Top 40 Healthcare Transformers dinner ... on May 10, 2017. The dinner followed a ... "beyond the pill."  "Innovation goes beyond invention," ...
Breaking Medicine Technology: